MedTrace Logo

Therapy of Preconditioned Autologous BMMSCs for Patients With Ischemic Heart Disease

NCT02504437 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2015-07-22

No results posted yet for this study

Summary

The purpose of the present study is to evaluate the efficacy of the preconditioned autologous bone marrow mesenchymal stem cells for patients with ischemic heart diseases.

Conditions

Interventions

BIOLOGICAL

BMMSCs

Sponsors & Collaborators

  • Sun Yat-sen University

    collaborator OTHER

  • Academy Military Medical Science, China

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2017-12-31
Completion
2017-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02504437 on ClinicalTrials.gov